Takeda To Create Wholly Owned Sales Units In Four Countries
This article was originally published in PharmAsia News
Executive SummaryTakeda Pharmaceutical says it plans to create sales and marketing units in four countries by the end of October. The firm said Belgium, Mexico, Sweden and Turkey are to be the new locations for Takeda wholly owned subsidiaries. The units are to sell the range of Takeda products, including its Actos (pioglitazone) drug for treating diabetes. (Click here for more - a subscription may be required
You may also be interested in...
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.